Screener
Eligibility screening
Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Participants With Moderately to Severely Active Systemic Lupus Erythematosus
57 US sites in AR, AZ, CA, CO +16
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.